Cyclin-dependent kinase 2 (CDK2) drives the progression of cells into the S-and M-phases
of the cell cycle. CDK2 activity is largely dispensable for normal development, but it is …

ABSTRACT CDK9 is a protein in constant development in cancer therapy. Herein we
present an overview of the enzyme as a target for cancer therapy. We provide data on its …

Summary Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through
RNAPII pause release. We now report that CDK9 is also essential for maintaining gene …

CDK1 is the only essential cell cycle CDK in human cells and is required for successful
completion of M-phase. It is the founding member of the CDK family and is conserved across …

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity,
resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the …

Dysregulation of the cell cycle characterizes many cancer subtypes, providing a rationale for
develo** cyclin-dependent kinase (CDK) inhibitors. Potent CDK2 inhibitors might target …

Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly
2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has …

Cyclin-dependent kinase 9 (CDK9), which regulates transcriptional elongation, is an
attractive therapeutic target for many cancers, especially for cancers driven by transcriptional …

The cyclin-dependent protein kinases (CDKs) are protein-serine/threonine kinases that
display crucial effects in regulation of cell cycle and transcription. While the excessive …

XChemExplorer (XCE) is a data-management and workflow tool to support large-scale
simultaneous analysis of protein–ligand complexes during structure-based ligand discovery …